Zynex, Inc. (ZYXI)
| Market Cap | 432.07M |
| Revenue (ttm) | 100.78M |
| Net Income (ttm) | 5.22M |
| Shares Out | 34.81M |
| EPS (ttm) | 0.15 |
| PE Ratio | 82.87 |
| Forward PE | 19.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,716 |
| Open | 12.34 |
| Previous Close | 12.32 |
| Day's Range | 12.16 - 12.49 |
| 52-Week Range | 10.66 - 22.89 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 23.40 (+88.3%) |
| Est. Earnings Date | Oct 26, 2021 |
About ZYXI
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary inco...
Financial Performance
In 2020, Zynex's revenue was $80.12 million, an increase of 76.20% compared to the previous year's $45.47 million. Earnings were $9.07 million, a decrease of -4.40%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Zynex stock is "Strong Buy." The 12-month stock price forecast is 23.40, which is an increase of 88.25% from the latest price.
News
Zynex Schedules 2021 Third Quarter Earnings Call
ENGLEWOOD, Colo., Oct. 25, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain man...
Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...
Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate
ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain manag...
Zynex to Display its CM-1500 Fluid Monitoring System at the American Society of Anesthesiologists Annual Conference
ENGLEWOOD, Colo., Oct. 8, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain mana...
Zynex Inc. (ZYXI) Surpasses Q2 Earnings Estimates
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and -0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex: Q2 Earnings Insights
Shares of Zynex (NASDAQ:ZYXI) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 11.11% year over year to $0.08, which beat the estim...
Zynex Announces 2021 Second Quarter Earnings
ENGLEWOOD, Colo., July 29, 2021 /PRNewswire/ -- 2021 Second Quarter Revenue increased 61% year over year to $31.0 million Orders increased 247% Net income of $2.8 million; Diluted EPS $0.08 Adjusted EBI...
Zynex Schedules 2021 Second Quarter Earnings Call
ENGLEWOOD, Colo., July 21, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain man...
Zynex Inc. (ZYXI) Stock Jumps 6.5%: Will It Continue to Soar?
Zynex Inc. (ZYXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zynex Announces 247% Order Growth and Increases Q2 Adjusted EBITDA Estimate
ENGLEWOOD, Colo., July 15, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain manag...
Zynex Announces Uplisting to the Nasdaq Global Select Market®
ENGLEWOOD, Colo., July 13, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain man...
Zynex to Present at the Ladenburg Thalmann Virtual Annual Healthcare Conference
ENGLEWOOD, Colo., July 8, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain mana...
Zynex Inc. (ZYXI) Reports Q1 Loss, Tops Revenue Estimates
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0.00% and 2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Announces 2021 First Quarter Earnings
ENGLEWOOD, Colo., April 29, 2021 /PRNewswire/ -- 2021 First Quarter Revenue increased 58% year over year to $24.1 million Orders increased 140% Net loss of $0.7 million; GAAP loss per share $0.02 Adjust...
Zynex Appoints Donald Gregg as Vice President of Sales and Operations of Monitoring Solutions Division
ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain ma...
Zynex Schedules 2021 First Quarter Earnings Call
ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain ma...
Zynex Announces 140% Year over Year Order Growth in Q1-2021
ENGLEWOOD, Colo., April 12, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain mana...
Zynex Growth Leads to New Corporate Headquarters
ENGLEWOOD, Colo., April 9, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain man...
Zynex Recognized as the Sixth Largest Biotechnology/Bioscience Company in Colorado
ENGLEWOOD, Colo., March 30, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain ma...
Airbnb, Centerpoint, Editas and More Friday Afternoon Analyst Calls
With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.
Why Zynex Stock Is Crashing Today
Investors are reacting negatively to the company's Q4 results and Q1 outlook.
Recap: Zynex Q4 Earnings
Shares of Zynex (NASDAQ:ZYXI) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 44.44% over the past year to $0.05, which missed the esti...
Zynex Announces 2020 Fourth Quarter and Full Year Earnings
ENGLEWOOD, Colo., Feb. 25, 2021 /PRNewswire/ -- 2020 Full Year Revenue increased 76% year over year to $80.1 million Orders increased 96% Net income of $9.1 million; Diluted EPS $0.26 Adjusted EBITDA $1...
Zynex Schedules 2020 Fourth Quarter and Full-Year Earnings Call
ENGLEWOOD, Colo., Feb. 18, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain man...
Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical
ENGLEWOOD, Colo., Jan. 28, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain man...